
    
      [Goal] To reveal the effect and safety of additional cilostazol for overcoming biochemical
      aspirin resistance.

      [Trial Design] Double-Blind, Placebo-Controlled, Randomized, Multicenter Trial

      [Participants] Ischemic stroke patients taking aspirin

      [Methods]

        -  Double-Blind, Placebo-Controlled, Randomized, Multicenter Trial

        -  Investigational product: Cilostazol 200mg (100mg twice per day)

        -  Concomitant medication: Aspirin 100 mg per day

        -  Medication Duration: 1 month

      [Outcome Variables]

      Primary Outcome Variable:

      • the proportion of patients with aspirin reaction units (ARUs) values ≥550 on the Ultra
      Rapid Platelet Function Assay-ASA

      Secondary outcome variables:

        -  the proportion of patients with ARUs values ≥500 on the Ultra Rapid Platelet Function
           Assay-ASA

        -  ARUs values

        -  Bleeding time (BT)

        -  Fatal or major bleeding complications

        -  Any bleeding complications
    
  